The Opioid Onslaught: Indictments, Civil Suits Strike Fear in Hearts of General Counsel at Opioid Companies
Experts say the opioid crisis in America has damaged 2.4 million people, claimed 300,000 lives and has cost the country over $500 billion in economic harm.
September 30, 2019 at 01:00 AM
8 minute read
Experts say the opioid crisis in America has damaged 2.4 million people, claimed 300,000 lives and has cost the country over $500 billion in economic harm. The damage—and an urgent quest to place civil and criminal blame for it—has created a fearsome time for general counsel and chief compliance officers at many U.S. companies that make, distribute or sell the drugs.
Increasingly general counsel are having to deal with criminal investigations and indictments of their drug companies, and sometimes of their own roles. One example was the indictment in April of the Rochester Drug Co-Operative in New York along with its chief compliance officer. In July prosecutors arrested the chief compliance officer of Miami-Luken Inc. for allegedly helping the company to illegally sell millions of dollars' worth of opioids.
Equally prevalent are civil lawsuits against drug makers, distributors and large retailers. Upcoming federal multidistrict litigation involving about 2,000 suits against some two dozen companies is scheduled to begin in October, although settlement talks are underway. These suits have been brought by 400 cities, counties, states and others to recover money spent on dealing with the epidemic and its health effects.
In a separate civil suit in late August, a county judge in Oklahoma ordered giant drug company Johnson & Johnson to pay $572 million to that state for its role in the crisis, citing false marketing strategies that misled health professionals and the public about the dangers of its drugs. Johnson & Johnson calls the ruling "flawed" and says it will appeal.
The company "did not cause the opioid crisis in Oklahoma, and neither the facts nor the law support this outcome," says a statement by Michael Ullmann, executive vice president and general counsel of Johnson & Johnson. "We recognize the opioid crisis is a tremendously complex public health issue and we have deep sympathy for everyone affected. We are working with partners to find ways to help those in need."
Indictments and Fear
The government wants in-house counsel to be scared, says Joshua Robbins, a former federal healthcare prosecutor and now chair of the white collar defense and government investigations practice at Greenberg Gross in Los Angeles. Robbins cites the federal government's press release in the Rochester case, which says it wanted "to send shock waves through the pharmaceutical industry" by indicting the company and two executives.
He noted that only a few executives were charged in both the Rochester and the Miami-Luken cases, and the chief compliance officer was among them. "That is not a random choice," he says.
"They want companies and compliance counsel to be afraid," Robbins continues. "There is an immense deterrent effect on any companies that would think about dismissing or minimizing their compliance obligations."
At least one company's history suggests the deterrence effect is not so immense. In 2007 Purdue Pharma and three executives, including its late general counsel Howard Udell, pleaded guilty to misbranding the opioid drug, Oxycontin. The three executives were banned from drug companies, seriously damaging their careers. Still Purdue Pharma remains the subject of lawsuits today.
As the Purdue Pharma history shows, it's not unprecedented to see the U.S. Department of Justice go after an in-house counsel or chief compliance officer. But Robbins says such action "is not typical, and I consider it to be pretty aggressive."
He adds that the recent indictments reflect DOJ's view "that perhaps a deliberate breakdown of the compliance function, knowing and willful, allowed companies to operate in violation of their regulatory obligations and to engage in conspiracies to distribute illegal products." Jacques Smith, national leader of Arent Fox's complex litigation group, agrees that the focus on individuals is a rising trend.
"The focus on individual accountability—as recently seen in DOJ's trend of going after executives of opioid drug companies—is not surprising," Smith says. "Individual accountability increased with the Yates Memo, was reinforced with some modifications under former [Deputy Attorney General Rod] Rosenstein, and has found permanence in the revised Justice Manual."
Other companies under recent DOJ scrutiny have negotiated their way out of criminal charges while reaching a civil settlement. In July, for example, DOJ announced reaching a nonprosecution agreement with the Reckitt Benckiser Group over sales and marketing of the opioid Suboxone. At the same time the government reached a $1.4 billion civil settlement which included the U.K.-based group and its subsidiary in New Jersey, Reckitt Benckiser LLC.
Civil Suits and "Abatement"
Unlike the criminal cases, the many civil lawsuits do not seek individual accountability as much as they demand money to cover the destruction wrought by opioids.
The Oklahoma decision came in the first civil trial of a drug maker over the damages caused by its painkillers. In following the tobacco litigation model, the suit sought $17 billion to cover the treatment and other services needed due to addictions in Oklahoma.
Judge Thad Balkman of Cleveland County District Court, however, lowered the amount to over half a million dollars as abatement for the damages caused by Johnson & Johnson. Before the trial, defendants Purdue Pharma and Teva Pharmaceuticals agreed to settle their parts in the case for $270 million and $85 million respectively, giving the state nearly $1 billion total.
The outcome in Oklahoma has no binding effect on other state cases nor on the huge multidistrict litigation before U.S. District Judge Dan Polster in Cleveland. Settlement talks are ongoing in that case at this writing.
In an unprecedented action, the Sackler family, owners of Purdue Pharma, has reportedly offered to give up ownership of the company and pay $3 billion for a global settlement that would end any new suits against family members or the company.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllBaker Botts' Biopharma Client Sues Former In-House Attorney, Others Alleging Extortion Scheme
People and Purpose: AbbVie's GC on Leading With Impact and Inspiring Change
7 minute readSage Therapeutics Axes GC After Drug-Pipeline Failures Force Cost-Cutting
After Guiding Illumina Through Harrowing Merger Fight, GC Charles Dadswell to Depart
Trending Stories
- 1Call for Nominations: Elite Trial Lawyers 2025
- 2Senate Judiciary Dems Release Report on Supreme Court Ethics
- 3Senate Confirms Last 2 of Biden's California Judicial Nominees
- 4Morrison & Foerster Doles Out Year-End and Special Bonuses, Raises Base Compensation for Associates
- 5Tom Girardi to Surrender to Federal Authorities on Jan. 7
Who Got The Work
Michael G. Bongiorno, Andrew Scott Dulberg and Elizabeth E. Driscoll from Wilmer Cutler Pickering Hale and Dorr have stepped in to represent Symbotic Inc., an A.I.-enabled technology platform that focuses on increasing supply chain efficiency, and other defendants in a pending shareholder derivative lawsuit. The case, filed Oct. 2 in Massachusetts District Court by the Brown Law Firm on behalf of Stephen Austen, accuses certain officers and directors of misleading investors in regard to Symbotic's potential for margin growth by failing to disclose that the company was not equipped to timely deploy its systems or manage expenses through project delays. The case, assigned to U.S. District Judge Nathaniel M. Gorton, is 1:24-cv-12522, Austen v. Cohen et al.
Who Got The Work
Edmund Polubinski and Marie Killmond of Davis Polk & Wardwell have entered appearances for data platform software development company MongoDB and other defendants in a pending shareholder derivative lawsuit. The action, filed Oct. 7 in New York Southern District Court by the Brown Law Firm, accuses the company's directors and/or officers of falsely expressing confidence in the company’s restructuring of its sales incentive plan and downplaying the severity of decreases in its upfront commitments. The case is 1:24-cv-07594, Roy v. Ittycheria et al.
Who Got The Work
Amy O. Bruchs and Kurt F. Ellison of Michael Best & Friedrich have entered appearances for Epic Systems Corp. in a pending employment discrimination lawsuit. The suit was filed Sept. 7 in Wisconsin Western District Court by Levine Eisberner LLC and Siri & Glimstad on behalf of a project manager who claims that he was wrongfully terminated after applying for a religious exemption to the defendant's COVID-19 vaccine mandate. The case, assigned to U.S. Magistrate Judge Anita Marie Boor, is 3:24-cv-00630, Secker, Nathan v. Epic Systems Corporation.
Who Got The Work
David X. Sullivan, Thomas J. Finn and Gregory A. Hall from McCarter & English have entered appearances for Sunrun Installation Services in a pending civil rights lawsuit. The complaint was filed Sept. 4 in Connecticut District Court by attorney Robert M. Berke on behalf of former employee George Edward Steins, who was arrested and charged with employing an unregistered home improvement salesperson. The complaint alleges that had Sunrun informed the Connecticut Department of Consumer Protection that the plaintiff's employment had ended in 2017 and that he no longer held Sunrun's home improvement contractor license, he would not have been hit with charges, which were dismissed in May 2024. The case, assigned to U.S. District Judge Jeffrey A. Meyer, is 3:24-cv-01423, Steins v. Sunrun, Inc. et al.
Who Got The Work
Greenberg Traurig shareholder Joshua L. Raskin has entered an appearance for boohoo.com UK Ltd. in a pending patent infringement lawsuit. The suit, filed Sept. 3 in Texas Eastern District Court by Rozier Hardt McDonough on behalf of Alto Dynamics, asserts five patents related to an online shopping platform. The case, assigned to U.S. District Judge Rodney Gilstrap, is 2:24-cv-00719, Alto Dynamics, LLC v. boohoo.com UK Limited.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250